-

MEDISCA and Fellow Industry Leaders Lobby for Revisions to Compounded Expiry Dates and Succeed

MASCOT, Australia--(BUSINESS WIRE)--Over the last several months, Medisca Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

In January 2021, the APF published revised standards where, in the absence of an APF formulary or stability study, compounding pharmacies are restricted to applying up to 28-day expiry dates on all compounded dosage forms, including capsules and powders that have historically received up to 6 months dating. A 28-day expiry date restriction on capsules and powders has the potential to drastically impact compounding pharmacy workflow efficiencies, cost to prepare medications, and most importantly, patient access to much needed personalised medications.

“Upon receiving the news of the change in capsule dating, we quickly ramped up efforts alongside fellow industry leaders and compounding pharmacies to express our concerns to the APF. Not only did the APF listen to us, they acted for us and, ultimately, the patients compounding pharmacy serves,” said Andrew Harb, General Manager for Medisca Australia and Emerging Markets. “The efforts of the last several months demonstrated what it means to be a community – and I and the Medisca team could not be prouder to be a part of it.”

After months of discussions and deliberations, effective as of 10 August 2021, the APF has revised the expiry date of compounded capsules and powders from up to 28 days to up to 6 months. This dating is applicable to capsules and powders that contain ingredients that are stable in air and not hygroscopic or deliquescent. This expiry date guidance is also applicable in the absence of an APF formula or stability study.

For additional support on how to assign an expiry date and access to a databank of stability-indicating studies for extended expiry dating visit: www.medisca.com.au/expiry-date.

About MEDISCA

MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalised medicine, MEDISCA offers high quality products, industry-leading support, and first-class education through its partner LP3 Network. Founded in 1989, the company has locations in Canada, the United States and Australia, optimising its service to the international market. For more information about MEDISCA, please visit www.medisca.com.au and follow us on Twitter at @medisca.

Contacts

Andrew Harb
Unit 7, Heritage Business Park
5-9 Ricketty Street, Mascot
NSW 2020, Australia
Medisca.com.au
1300 786 392

MEDISCA


Release Versions

Contacts

Andrew Harb
Unit 7, Heritage Business Park
5-9 Ricketty Street, Mascot
NSW 2020, Australia
Medisca.com.au
1300 786 392

Social Media Profiles
More News From MEDISCA

Medisca Launches Global Peptide Division

MONTREAL--(BUSINESS WIRE)--Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term comm...

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

MONTREAL--(BUSINESS WIRE)--For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was...

Medisca and dsm–firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market

MONTREAL--(BUSINESS WIRE)--Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide. Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and su...
Back to Newsroom